← All trials

NCT04844749

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jun 24, 2021
Primary completion
Apr 29, 2024
Completion date
Aug 19, 2024
First posted
Apr 14, 2021
Last posted
Dec 1, 2021
Enrollment
245
Arms / groups
2 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.